Abstract
Several medications are associated with retinal vascular toxicity. These include intraocular aminoglycosides, oral contraceptives, interferon alpha, several other agents, and talc, which occurs as a vehicle in some oral medications that may be abused intravenously. As a group, these entities represent a small but clinically relevant category of retinal toxicity from medications. Some of the manifestations (e.g., retinal vascular occlusion) are nonspecific, but others are more specific, including clinically visible talc emboli in retinal vessels. Toxicity may be asymptomatic or may cause irreversible visual loss. By maintaining a high index of suspicion, the correct diagnosis can usually be made.
Keywords: Retinal vascular toxicity, aminoglycosides, talc, oral contraceptives, interferon alpha.
Current Pharmaceutical Design
Title:Update on Pharmacologic Retinal Vascular Toxicity
Volume: 21 Issue: 32
Author(s): Stephen G. Schwartz, Andrzej Grzybowski, Weronika Wasinska-Borowiec, Harry W. Flynn and William F. Mieler
Affiliation:
Keywords: Retinal vascular toxicity, aminoglycosides, talc, oral contraceptives, interferon alpha.
Abstract: Several medications are associated with retinal vascular toxicity. These include intraocular aminoglycosides, oral contraceptives, interferon alpha, several other agents, and talc, which occurs as a vehicle in some oral medications that may be abused intravenously. As a group, these entities represent a small but clinically relevant category of retinal toxicity from medications. Some of the manifestations (e.g., retinal vascular occlusion) are nonspecific, but others are more specific, including clinically visible talc emboli in retinal vessels. Toxicity may be asymptomatic or may cause irreversible visual loss. By maintaining a high index of suspicion, the correct diagnosis can usually be made.
Export Options
About this article
Cite this article as:
Schwartz G. Stephen, Grzybowski Andrzej, Wasinska-Borowiec Weronika, Flynn W. Harry and Mieler F. William, Update on Pharmacologic Retinal Vascular Toxicity, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150909101621
DOI https://dx.doi.org/10.2174/1381612821666150909101621 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Molecular Understanding and Future Treatment Strategies for Pathologic Ocular Neovascularization
Current Molecular Medicine Nucleoside Transporter Proteins
Current Vascular Pharmacology Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Compromise and Care of the Brains Compartments: The Quintessence of the Neurovascular Unit
Current Neurovascular Research Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Application of Hydrogen in Ophthalmology
Current Pharmaceutical Design Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued) Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Measurement and Mapping of Retinal Leakage and Retinal Thickness - Surrogate Outcomes for the Initial Stages of Diabetic Retinopathy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design An update on the Management and Treatment of Deep Vein Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Stroke in Women
Recent Patents on Cardiovascular Drug Discovery Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued) Structure and Function of Myelinated Nerve Fibers in the Rabbit Eye Following Ischemia/Reperfusion Injury
Current Neurovascular Research